Literature DB >> 18598021

Molecular docking of cathepsin L inhibitors in the binding site of papain.

Mary Pat Beavers1, Michael C Myers, Parag P Shah, Jeremy E Purvis, Scott L Diamond, Barry S Cooperman, Donna M Huryn, Amos B Smith.   

Abstract

The papain/CLIK-148 coordinate system was employed as a model to study the interactions of a nonpeptide thiocarbazate inhibitor of cathepsin L ( 1). This small molecule inhibitor, a thiol ester containing a diacyl hydrazine functionality and one stereogenic center, was most active as the S-enantiomer, with an IC 50 of 56 nM; the R-enantiomer ( 2) displayed only weak activity (33 microM). Correspondingly, molecular docking studies with Extra Precision Glide revealed a correlation between score and biological activity for the two thiocarbazate enantiomers when a structural water was preserved. The molecular interactions between 1 and papain were very similar to the interactions observed for CLIK-148 ( 3a and 3b) with papain, especially with regard to the hydrogen-bonding and lipophilic interactions of the ligands with conserved residues in the catalytic binding site. Subsequent docking of virtual compounds in the binding site led to the identification of a more potent inhibitor ( 5), with an IC 50 of 7.0 nM. These docking studies revealed that favorable energy scores and correspondingly favorable biological activities could be realized when the virtual compound design included occupation of the S2, S3, and S1' subsites by hydrophobic and aromatic functionalities of the ligand, and at least three hydrogen bonding contacts between the ligand and the conserved binding site residues of the protein.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18598021      PMCID: PMC2923042          DOI: 10.1021/ci800085c

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  21 in total

1.  The Protein Data Bank.

Authors:  H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

Review 2.  Target-based drug discovery for malaria, leishmaniasis, and trypanosomiasis.

Authors:  K A Werbovetz
Journal:  Curr Med Chem       Date:  2000-08       Impact factor: 4.530

3.  Crystal structure of papain-E64-c complex. Binding diversity of E64-c to papain S2 and S3 subsites.

Authors:  M J Kim; D Yamamoto; K Matsumoto; M Inoue; T Ishida; H Mizuno; S Sumiya; K Kitamura
Journal:  Biochem J       Date:  1992-11-01       Impact factor: 3.857

4.  Kinetic characterization and molecular docking of a novel, potent, and selective slow-binding inhibitor of human cathepsin L.

Authors:  Parag P Shah; Michael C Myers; Mary Pat Beavers; Jeremy E Purvis; Huiyan Jing; Heather J Grieser; Elizabeth R Sharlow; Andrew D Napper; Donna M Huryn; Barry S Cooperman; Amos B Smith; Scott L Diamond
Journal:  Mol Pharmacol       Date:  2008-04-10       Impact factor: 4.436

5.  Design of noncovalent inhibitors of human cathepsin L. From the 96-residue proregion to optimized tripeptides.

Authors:  Shafinaz F Chowdhury; J Sivaraman; Jing Wang; Gopal Devanathan; Paule Lachance; Hongtao Qi; Robert Ménard; Jean Lefebvre; Yasuo Konishi; Miroslaw Cygler; Traian Sulea; Enrico O Purisima
Journal:  J Med Chem       Date:  2002-11-21       Impact factor: 7.446

6.  Identification of Leishmania major cysteine proteinases as targets of the immune response in humans.

Authors:  S Rafati; A H Salmanian; K Hashemi; C Schaff; S Belli; N Fasel
Journal:  Mol Biochem Parasitol       Date:  2001-03       Impact factor: 1.759

7.  On the size of the active site in proteases. I. Papain.

Authors:  I Schechter; A Berger
Journal:  Biochem Biophys Res Commun       Date:  1967-04-20       Impact factor: 3.575

Review 8.  Cysteine proteinases and the pathogenesis of amebiasis.

Authors:  X Que; S L Reed
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

9.  Overexpression of cruzipain, the major cysteine proteinase of Trypanosoma cruzi, is associated with enhanced metacyclogenesis.

Authors:  A M Tomas; M A Miles; J M Kelly
Journal:  Eur J Biochem       Date:  1997-03-01

10.  Functional expression of falcipain, a Plasmodium falciparum cysteine proteinase, supports its role as a malarial hemoglobinase.

Authors:  F Salas; J Fichmann; G K Lee; M D Scott; P J Rosenthal
Journal:  Infect Immun       Date:  1995-06       Impact factor: 3.441

View more
  11 in total

1.  Design, synthesis and biological evaluation of a library of thiocarbazates and their activity as cysteine protease inhibitors.

Authors:  Zhuqing Liu; Michael C Myers; Parag P Shah; Mary Pat Beavers; Phillip A Benedetti; Scott L Diamond; Amos B Smith; Donna M Huryn
Journal:  Comb Chem High Throughput Screen       Date:  2010-05       Impact factor: 1.339

Review 2.  Microbial inhibitors of cysteine proteases.

Authors:  Mateusz Kędzior; Rafał Seredyński; Jan Gutowicz
Journal:  Med Microbiol Immunol       Date:  2016-04-05       Impact factor: 3.402

3.  Multi-conformation 3D QSAR study of benzenesulfonyl-pyrazol-ester compounds and their analogs as cathepsin B inhibitors.

Authors:  Zhigang Zhou; Yanli Wang; Stephen H Bryant
Journal:  J Mol Graph Model       Date:  2011-07-07       Impact factor: 2.518

4.  A small-molecule oxocarbazate inhibitor of human cathepsin L blocks severe acute respiratory syndrome and ebola pseudotype virus infection into human embryonic kidney 293T cells.

Authors:  Parag P Shah; Tianhua Wang; Rachel L Kaletsky; Michael C Myers; Jeremy E Purvis; Huiyan Jing; Donna M Huryn; Doron C Greenbaum; Amos B Smith; Paul Bates; Scott L Diamond
Journal:  Mol Pharmacol       Date:  2010-05-13       Impact factor: 4.436

Review 5.  The identification, characterization and optimization of small molecule probes of cysteine proteases: experiences of the Penn Center for Molecular Discovery with cathepsin B and cathepsin L.

Authors:  Donna M Huryn; Amos B Smith
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

6.  Computational analysis of the cathepsin B inhibitors activities through LR-MMPBSA binding affinity calculation based on docked complex.

Authors:  Zhigang Zhou; Yanli Wang; Stephen H Bryant
Journal:  J Comput Chem       Date:  2009-11-15       Impact factor: 3.376

7.  QSAR models for predicting cathepsin B inhibition by small molecules--continuous and binary QSAR models to classify cathepsin B inhibition activities of small molecules.

Authors:  Zhigang Zhou; Yanli Wang; Stephen H Bryant
Journal:  J Mol Graph Model       Date:  2010-02-01       Impact factor: 2.518

8.  Is It Reliable to Use Common Molecular Docking Methods for Comparing the Binding Affinities of Enantiomer Pairs for Their Protein Target?

Authors:  David Ramírez; Julio Caballero
Journal:  Int J Mol Sci       Date:  2016-04-20       Impact factor: 5.923

Review 9.  Cell entry of enveloped viruses.

Authors:  François-Loic Cosset; Dimitri Lavillette
Journal:  Adv Genet       Date:  2011       Impact factor: 1.944

10.  High throughput virtual screening reveals SARS-CoV-2 multi-target binding natural compounds to lead instant therapy for COVID-19 treatment.

Authors:  Biswajit Naik; Nidhi Gupta; Rupal Ojha; Satyendra Singh; Vijay Kumar Prajapati; Dhaneswar Prusty
Journal:  Int J Biol Macromol       Date:  2020-05-26       Impact factor: 6.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.